Since glucocorticoids were first used to treat patients with rheumatoid arthritis in 1949, they have become the most common therapy for inflammatory disorders; however, their use is associated with major metabolic adverse events. Here, we review three 2015 reports with clinical and fundamental implications for the use of glucocorticoid therapy in rheumatology.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hillier, S. G. Diamonds are forever: the cortisone legacy. J. Endocrinol. 195, 1–6 (2007).
Ruiz-Arruza, I. et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53, 1470–1476 (2014).
Thamer, M., Hernan, M. A., Zhang, Y., Cotter, D. & Petri, M. Prednisone, lupus activity, and permanent organ damage. J. Rheumatol. 36, 560–564 (2009).
Chen, S. Y. et al. Glucocorticoid use in patients with systemic lupus erythematosus: association between dose and health care utilization and costs. Arthritis Care Res. (Hoboken) 67, 1086–1094 (2015).
Beaulieu, E. & Morand, E. F. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 340–348 (2011).
Jones, S. A. et al. GILZ regulates TH17 responses and restrains IL-17-mediated skin inflammation. J. Autoimmun. 61, 73–80 (2015).
Bruscoli, S. et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B cell survival and results in B cell lymphocytosis in mice. Blood 126, 1790–1801 (2015).
Jones, S. A. et al. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-207744 (2015).
Jones, S. A., Sutton, C. E., Cua, D. & Mills, K. H. Therapeutic potential of targeting IL-17. Nat. Immunol. 13, 1022–1025 (2012).
Schewitz-Bowers, L. P. et al. Glucocorticoid-resistant TH17 cells are selectively attenuated by cyclosporine A. Proc. Natl Acad. Sci. USA 112, 4080–4085 (2015).
The authors wish to thank the Lupus Research Institute, the National Health and Medical Research Council of Australia and the Ulysses Club Arthritis Research Fund for funding their work.
The authors declare no competing financial interests.
About this article
Cite this article
Jones, S., Morand, E. New answers to old problems. Nat Rev Rheumatol 12, 73–74 (2016). https://doi.org/10.1038/nrrheum.2015.176
Reviews in Endocrine and Metabolic Disorders (2016)